Breaking News

Coeptis Launches New Technology Division

Signs a binding letter of intent to acquire key assets from a risk mitigation software company with 10,000 customers in over 100 countries.

Author Image

By: Charlie Sternberg

Associate Editor

Coeptis Therapeutics Holdings Inc., a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, has launched Coeptis Technologies, a new division aimed at diversifying and enhancing the company’s growth potential.   In line with this move, Coeptis Technologies has signed a binding Letter of Intent (LOI) with a leading company in the data security software industry with over 10,000 customers in over 100 countries. This LOI outl...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters